New distribution! Reach relevant USA TODAY Network news sites. Get started ›

New distribution! Reach relevant USA TODAY Network news sites. Get started ›

World Media Directory · RSS · Email Newsletters

There were 1,543 press releases posted in the last 24 hours and 479,768 in the last 365 days.

Biomed Industries, Inc. Press Releases

39 Press Releases

Published on July 16, 2026 - 10:00 GMT

Biomed Industries Presents Promising Phase 2/3 Clinical Results of NA-921 for Rett Syndrome at Orphan Drug Summit 2026

Biomed Industries Presents Promising Phase 2/3 Clinical Results of NA-921 for Rett Syndrome at Orphan Drug Summit 2026 Advancing Named Patient Access Initiative SAN JOSE, CA, UNITED STATES, July 16, 2026 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc., a …

Distribution channels: Chemical Industry, Companies ...
Published on June 10, 2026 - 10:00 GMT

Biomed Industries Presents Phase 3 Programs of NA-931 Alone and Combining With Oral Semaglutide for Obesity at ADA 2026

Biomed Industries Presents Global Phase 3 Programs of NA-931 as Monotherapy and in Combination With Oral Semaglutide for Obesity at ADA 2026 in New Orleans SAN JOSE, CA, UNITED STATES, June 10, 2026 /⁨EINPresswire.com⁩/ -- First-in-class oral quadruple …

Distribution channels: Chemical Industry, Companies ...
Published on May 5, 2026 - 09:00 GMT

Biomed Industries, Inc. Advances Dual-Track Obesity Therapy Strategy with Near-Term Revenue and NA-931 Phase 3 Launch

Biomed Industries, Inc. Advances Dual-Track Obesity Therapy Strategy with Near-Term Revenue from Bioxentra Life Sciences, Inc. and NA-931 Phase 3 Launch SAN JOSE, CA, UNITED STATES, May 5, 2026 /⁨EINPresswire.com⁩/ -- — Biomed Industries, Inc. today …

Distribution channels: Chemical Industry, Companies ...
Published on March 18, 2026 - 10:00 GMT

Biomed Industries Presented Breakthrough Unified Theory Linking Alzheimer’s Disease, Obesity & Cardiovascular Diseases

Biomed Industries, Inc. Presented Breakthrough Unified Theory Linking Alzheimer’s Disease, Obesity and Cardiovascular Disease at Global Neuroscience Summit 2026 SAN JOSE, CA, UNITED STATES, March 18, 2026 /⁨EINPresswire.com⁩/ -- – Biomed Industries, Inc. …

Distribution channels: Chemical Industry, Companies ...
Published on January 19, 2026 - 16:21 GMT

Biomed Industries Announces Phase 3 Trials of NA-931 Targeting Durable Weight Loss & Lean-Mass Preservation at JPM Week

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation at JP Morgan Week 2026 SAN JOSE, CA, UNITED STATES, January 19, 2026 /⁨EINPresswire.com⁩/ -- — Biomed Industries, Inc., a clinical- …

Distribution channels: Chemical Industry, Companies ...
Published on January 6, 2026 - 11:00 GMT

Biomed Industries Advances NA-931 Into Two Global Phase 3 Trials Alone and with Semaglutide and Tirzepatide for Obesity

Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity SAN JOSE, CA, UNITED STATES, January 6, 2026 /⁨EINPresswire.com⁩/ -- — Biomed Industries, Inc. (“Biomed”), a …

Distribution channels: Chemical Industry, Companies ...
Published on November 26, 2025 - 11:00 GMT

Biomed Industries to Present Four Transformative Studies on Alzheimer’s Disease, Obesity, and Stroke at CTAD 2025

Biomed Industries to Present Four Transformative Studies on NA-831 for Alzheimer’s Disease, NA-931 for Obesity, and NA-911 for Stroke at CTAD 2025 - San Diego SAN JOSE, CA, UNITED STATES, November 26, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc …

Distribution channels: Chemical Industry, Companies ...
Published on October 30, 2025 - 10:00 GMT

Biomed Industries to Present Phase 2 Data on NA-931—an Oral Alternative to Injectables for Obesity—at ObesityWeek® 2025

Biomed Industries, Inc. to Present Breakthrough Phase 2 Data on NA-931—an Oral Alternative to Injectables for Obesity—at ObesityWeek® 2025 SAN JOSE, CA, UNITED STATES, October 30, 2025 /⁨EINPresswire.com⁩/ -- — Biomed Industries, Inc. (“Biomed”) today …

Distribution channels: Chemical Industry, Companies ...
Published on September 30, 2025 - 13:30 GMT

Biomed Industries, Inc. Unveils Phase 2 Success of NA-931: an Oral Quadruple Receptor Agonist for Obesity at EASD 2025

Biomed Industries, Inc. Unveils Phase 2 Success of NA-931: a First-in Class Oral Quadruple Receptor Agonist for the Treatment of Obesity at EASD 2025 in Vienna SAN JOSE, CA, UNITED STATES, September 30, 2025 /⁨EINPresswire.com⁩/ -- - Biomed Industries, …

Distribution channels: Chemical Industry, Companies ...
Published on September 8, 2025 - 10:00 GMT

Biomed Industries to Present Phase 2 Results on NA-931-An Oral Alternative to Injectables for Obesity- EASD 2025 Austria

Biomed Industries, Inc. to Present Phase 2 Results on NA-931-a First-in Class Alternative to Injectables for the Treatment of Obesity-EASD 2025- Vienna-Austria SAN JOSE, CA, UNITED STATES, September 8, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc …

Distribution channels: Chemical Industry, Companies ...
Published on September 2, 2025 - 10:00 GMT

Biomed Industries to Present Pivotal Studies at Paris MASH 2025 with Breakthrough in Obesity and Liver Disease Therapies

Company to present clinical trial protocols for NA 941 and cross indication data readouts for NA 931/NA 941 supporting development in obesity and MASH. SAN JOSE, CA, UNITED STATES, September 2, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc., a …

Distribution channels: Chemical Industry, Companies ...
Published on August 20, 2025 - 18:36 GMT

Biomed Industries, Inc. Advances First-of-Its-Kind Oral NA-931 and Semaglutide Combination Therapy for Treating Obesity

Biomed Industries, Inc. Advances First-of-Its-Kind Oral NA-931 (Bioglutide) and Injectable Semaglutide Combination Therapy for the Treatment of Obesity SAN JOSE, CA, UNITED STATES, August 20, 2025 /⁨EINPresswire.com⁩/ -- SAN JOSE, Calif., Aug. 20, 2025 …

Distribution channels: Chemical Industry, Companies ...
Published on August 4, 2025 - 10:00 GMT

Biomed Industries Presents Four Breakthrough Studies on Alzheimer’s, Rett Syndrome, and Obesity Therapies at AAIC 2025

Biomed Industries, Inc. Presents Four Pivotal Studies at AAIC 2025 Highlighting Breakthrough Therapies for Alzheimer’s, Rett Syndrome, and Obesity SAN JOSE, CA, UNITED STATES, August 4, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc., a leading …

Distribution channels: Chemical Industry, Companies ...
Published on July 22, 2025 - 10:00 GMT

Biomed Industries to Present Four Studies at AAIC 2025 on Breakthrough Alzheimer’s, Rett Syndrome, and Obesity Therapies

Biomed Industries, Inc. to Present Four Pivotal Studies at AAIC 2025 on Breakthrough Alzheimer’s, Rett Syndrome, and Obesity Therapies SAN JOSE, CA, UNITED STATES, July 22, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc., a leading biopharmaceutical …

Distribution channels: Chemical Industry, Companies ...
Published on July 17, 2025 - 10:00 GMT

Biomed Industries Unveils Promising Phase 2 Results of NA-931, First Oral Quadruple Agonist for Obesity at ENDO 2025

Biomed Industries, Inc. Unveils Promising Phase 2 Results of NA-931, First Oral Quadruple Receptor Agonist for the Treatment of Obesity at ENDO 2025 SAN JOSE, CA, UNITED STATES, July 17, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (Biomed) today …

Distribution channels: Chemical Industry, Companies ...
Published on June 23, 2025 - 10:00 GMT

Biomed Industries Presents Breakthrough Phase 2 Results of NA-931, an Oral Quadruple Agonist for Obesity , at ADA 2025

Biomed Industries, Inc. Presents Breakthrough Phase 2 Results of NA-931, a First-in-Class Oral Quadruple Agonist for the Treatment of Obesity , at ADA 2025 SAN JOSE, CA, UNITED STATES, June 23, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. ( …

Distribution channels: Chemical Industry, Companies ...
Published on June 17, 2025 - 10:00 GMT

Biomed Industries, Inc. to Present Phase 2 Results of Oral Obesity Drug NA-931 and Host Press Conference at ADA 2025

Biomed Industries, Inc. to Present Phase 2 Results of NA-931, a First-in-Class Oral Therapy for Obesity, and Host a Press Conference at the ADA 025 SAN JOSE, CA, UNITED STATES, June 17, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (Biomed) today …

Distribution channels: Chemical Industry, Companies ...
Published on June 11, 2025 - 10:00 GMT

Biomed Industries, Inc. to Unveil Unified Acceleration Platform at ADA 2025, Linking Alzheimer’s, Obesity, and Diabetes

Biomed Industries, Inc. to Unveil Unified Acceleration Platform at American Diabetes Association (ADA) 2025, Linking Alzheimer’s, Obesity, and Diabetes SAN JOSE, CA, UNITED STATES, June 11, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (“Biomed”) …

Distribution channels: Chemical Industry, Companies ...
Published on May 5, 2025 - 11:32 GMT

Biomed Industries, Inc. to Present Phase 2 Results on NA-931—An Oral Alternative to Injectables for Obesity—at ADA 2025

Biomed Industries, Inc. to Present Phase 2 Results on NA-931—An Oral Medicine Alternative to Injectables for Obesity—at ADA Conference 2025 in Chicago SAN JOSE, CA, UNITED STATES, May 5, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (“Biomed”) …

Distribution channels: Chemical Industry, Companies ...
Published on March 31, 2025 - 10:00 GMT

Biomed Industries CEO to Chair NeuroSciences 2025 and Present Breakthrough Research on Alzheimer’s Disease and Obesity

Biomed Industries, Inc. CEO to Chair NeuroSciences 2025 and Present Groundbreaking Research on Alzheimer’s, Obesity, and Rett Syndrome SAN JOSE, CA, UNITED STATES, March 31, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (Biomed) announced today …

Distribution channels: Chemical Industry, Companies ...

1 2 Next